Teladoc Health (TDOC)
(Delayed Data from NYSE)
$11.24 USD
-0.05 (-0.44%)
Updated May 31, 2024 04:00 PM ET
After-Market: $11.25 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Teladoc (TDOC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.29 | $25.00 | $12.00 | 53.14% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Teladoc comes to $17.29. The forecasts range from a low of $12.00 to a high of $25.00. The average price target represents an increase of 53.14% from the last closing price of $11.29.
Analyst Price Targets (19)
Broker Rating
Teladoc currently has an average brokerage recommendation (ABR) of 2.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 2.54 a month ago based on 24 recommendations.
Of the 24 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 20.83% and 4.17% of all recommendations. A month ago, Strong Buy made up 20.83%, while Buy represented 4.17%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 18 | 18 | 18 | 17 | 17 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.54 | 2.54 | 2.54 | 2.52 | 2.52 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Evercore Partners | Elizabeth Anderson | Not Available | Hold |
4/26/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
4/26/2024 | D.A. Davidson | Gil Luria | Hold | Hold |
4/5/2024 | Needham & Company | Ryan Macdonald | Hold | Hold |
3/8/2024 | William Blair | Ryan S Daniels | Hold | Hold |
3/6/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/29/2024 | Cantor Fitzgerald & Co | Sarah James | Not Available | Strong Buy |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
2/21/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
1/2/2024 | BTIG | David M Larsen | Not Available | Hold |
11/1/2023 | Stephens | Jeffrey Garro | Hold | Hold |
10/25/2023 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.54 |
ABR (Last week) | 2.54 |
# of Recs in ABR | 24 |
Average Target Price | $17.29 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.35 |